Differences in Structural Proteins in Prostate Cells May GiveEarly Indications of Cancer

Publication
Article
OncologyONCOLOGY Vol 9 No 8
Volume 9
Issue 8

Variations in structural proteins found in the nucleus of prostatecells may indicate whether a cell will become cancerous, according

Variations in structural proteins found in the nucleus of prostatecells may indicate whether a cell will become cancerous, accordingto a Pittsburgh Cancer Institute (PCI) investigator.

Robert Getzenberg, PhD, Assistant Professor of Pathology, Surgery,Medicine and Pharmacology at PCI, presented his findings at theannual meeting of the American Urological Association in Las Vegas.Dr. Getzenberg's research focuses on nuclear alterations thatare prevalent in prostate cancer cells and are commonly used asa pathological marker for cancer.

Researchers looked at structural proteins within the cell's nucleus.These proteins form the "scaffolding framework" of thenucleus, and are involved in DNA organization. "When we startedlooking at the nuclear matrix proteins in the cells of prostatetissue, we found that there is a difference between normal andcancer cells," Dr. Getzenberg said.

Variations in nuclear matrix proteins may be a useful tool fordiagnosing early stages of prostate cancer, and may offer newstrategies for treatment, according to the investigators.

Dr. Getzenberg and his colleagues identified proteins that werepresent only in the normal prostate and were missing in both prostatecancer and benign prostatic hyperplasia (BPH); proteins foundonly in the prostate cancer cells and missing in the normal prostateand BPH; and proteins that appeared in both normal and BPH samplesbut were absent from prostate cancers.

"Differences in nuclear matrix proteins may be a fundamentalcause of, or a major contributor to, the pattern of altered geneexpression identified in prostate cancer," Dr. Getzenbergsaid.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.